Trial · NCT01733680
Amiloride Hydrochloride as an Effective Treatment for ADHD
NCT01733680, Early phase 1, Terminated, State University of New York - Upstate Medical University; results first posted 2018-07-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Amiloride Hydrochloride as an Effective Treatment for ADHD. Trials, record NCT01733680. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01733680
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Amiloride Hydrochloride as an Effective Treatment for ADHD
- NCT number
- NCT01733680
- Status
- Terminated
- Phases
- Early phase 1
- Enrollment
- 3 participants, actual
- Lead sponsor
- State University of New York - Upstate Medical University
- Conditions
- ADHD
- Interventions
- amiloride, Behavioral
- First posted
- 2012-11-27
- Last updated
- 2018-07-20
- Results first posted
- 2018-07-20
- Limitations and caveats
- Because of the low number of subjects enrolled in the study, no outcome measures were statistically analyzed.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Improvement in CGI | 8 weeks | CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse |
| Secondary | AISRS, Adult ADHD Investigator Rating Scale | 8 weeks | An 18 item clinician administered questionnaire to evaluate ADHD in adults. Responses to questions were 0-None, 1-Mild, 2-Moderate, 3-Severe. A decrease of 30% in the total score would be considered improvement. Total score range is 0-54. A lower score indicates improvement in symptoms. A score of 24 or more indicates symptomatic ADHD. |
| Secondary | The Behavior Rating Inventory of Executive Function-Adult (BRIEF-A) | 8 weeks | BRIEF-A is a 75 item self report questionnaire that measures behavior and executive function. For each item the subject is asked "during the past month, how often has each of the following behaviors been a problem?:" The choices are N (never), S (sometimes), O (Often). Total score for the Global Executive Composite used. Raw data were transformed into t-scores, which are standardized scores that indicate the number of standard deviations away from the mean. A T-score of 50 is equal to the mean. Values less than 65 indicate executive function is not a problem and values greater than 65 indicate executive function is often a problem. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Improvement in CGI | 8 weeks | There was no statistical analysis done due to the small number of participants in the study | Units on a scale | MEAN |
| SECONDARY | AISRS, Adult ADHD Investigator Rating Scale | 8 weeks | Statistical analysis of the outcome data was not done due to the small N. | Total score | MEAN |
| SECONDARY | The Behavior Rating Inventory of Executive Function-Adult (BRIEF-A) | 8 weeks | Statistical analysis of the outcome data was not done due to the small N of each group | Global Executive Composite T Score | MEAN |
Source ClinicalTrials.gov
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Improvement in CGI | Amiloride | CGI Week 3 | 4 | Full Range 4 to 4 | Units on a scale |
| Improvement in CGI | Placebo | CGI Week 3 | 5 | Full Range 5 to 5 | Units on a scale |
| Improvement in CGI | Amiloride | CGI Week 4 | 4 | Full Range 4 to 4 | Units on a scale |
| Improvement in CGI | Placebo | CGI Week 4 | 3 | Full Range 3 to 3 | Units on a scale |
| Improvement in CGI | Amiloride | CGI Week 5 | 4 | Full Range 4 to 4 | Units on a scale |
| Improvement in CGI | Placebo | CGI Week 5 | 5 | Full Range 5 to 5 | Units on a scale |
| Improvement in CGI | Amiloride | CGI Week 6 | 3.5 | Full Range 3 to 4 | Units on a scale |
| Improvement in CGI | Placebo | CGI Week 6 | 5 | Full Range 5 to 5 | Units on a scale |
| Improvement in CGI | Amiloride | CGI Week 7 | 4 | Full Range 4 to 4 | Units on a scale |
| Improvement in CGI | Placebo | CGI Week 7 | 5 | Full Range 5 to 5 | Units on a scale |
1 to 10 of 48Source ClinicalTrials.gov
See all 48 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Amiloride | 2 | |
| Overall Study | STARTED | Placebo | 1 | |
| Overall Study | COMPLETED | Amiloride | 2 | |
| Overall Study | COMPLETED | Placebo | 0 | |
| Overall Study | NOT COMPLETED | Amiloride | 0 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Amiloride | ||
| Total, all-cause mortality | Placebo | ||
| Total, other adverse events | Amiloride | 0 | 2 |
| Total, other adverse events | Placebo | 0 | 1 |
| Total, serious adverse events | Amiloride | 0 | 2 |
| Total, serious adverse events | Placebo | 0 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Amiloride vs Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01733680
GET https://conductscience.org/api/trials/v1/NCT01733680/results?page=2